Why Regeneron (REGN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Why Regeneron (REGN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
More News
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD
BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.
Zacks
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.
Stocktwits
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.
Zacks
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
Zacks
Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights
Sanofi and Regeneron are broadening their immunology pipeline while keeping their existing Dupixent economics intact.
Stocktwits
Sanofi & Regeneron Expand Alliance With Four Next-Gen Antibodies
(RTTNews) - On Thursday, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced the expansion of their global collaboration to develop and commercialize four next-generation, long-acting immunology antibodies targeting type 2 inflammation...
Nasdaq News: Markets
REGN or ILMN: Which Is the Better Value Stock Right Now?
REGN vs. ILMN: Which Stock Is the Better Value Option?
Zacks
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
Zacks
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.